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Steroid-nonresponsive acute graft-versus-host disease (aGVHD) after hematopoietic stem cell transplantation
carries a poor prognosis. Various groups have reported beneﬁcial effects of mesenchymal stromal cell (MSC)
infusion as salvage treatment. Response to treatment is typically evaluated using the diagnostic clinical
criteria for aGVHD. In this study, we evaluated the usefulness of additional gastrointestinal biopsy specimens
paired with serum biomarkers. In a cohort of 22 pediatric patients, persistent or recurrent diarrhea was seen
in 18 children treated with MSC infusion for steroid-refractory aGVHD. To exclude other causes of gastro-
intestinal pathology, patients were biopsied for histological analysis. Eight of 12 patients exhibited residual
tissue damage and villous atrophy, but no active aGVHD. Serum biomarkers have been identiﬁed as an
alternative tool for monitoring the response to aGVHD treatment. The value of biomarkers for inﬂammation,
tissue, and endothelial cell damage was evaluated in our cohort. Although predictive of response to treatment
and survival, these markers lack the necessary speciﬁcity and sensitivity to predict response to MSC therapy.
Objective endpoints for clinical trials on the treatment of steroid-refractory aGVHD remain to be deﬁned.
Thus, we recommend including biopsies and biomarkers to discriminate between ongoing aGVHD and
postinﬂammatory malabsorption.
 2013 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.INTRODUCTION
Acute graft-versus-host disease (aGVHD) is a major
complication after allogeneic hematopoietic stem cell trans-
plantation (HSCT), mediated by alloreactive donor T lympho-
cytes targeting the skin, gut, and liver [1,2]. Gastrointestinal
(GI) aGVHD is clinically graded according to the volume of
diarrhea, severity of abdominal pain, and presence of paralytic
ileus [3]. Children with the most severe forms, namely grade
III-IV aGVHD, have substantially reduced survival, especially
those who are refractory to initial treatment with systemic
steroids [4,5].
Mesenchymal stromal cells (MSCs) are nonhematopoietic
cells capable of inducing immunosuppressive and anti-
inﬂammatory effects [6,7]. MSCs were ﬁrst administered to
a child with steroid-refractory aGVHD in 2004, leading to
resolution of symptoms [8]. Subsequent studies reported
response rates to MSC therapy for aGVHD ranging from
30% to 80%, with a trend toward a better response in children
[9-13]. These studies used different endpoints to documentedgments on page 1598.
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[9] or response on day 28 to 32 after treatment initiation [10-
13]. One as-yet unpublished study that randomized patients
for treatment with either MSCs and steroids or steroids only
did not conﬁrm those observations [14].
Nonetheless, in all studies to date, irrespective of out-
come, evaluation of the response to MSC treatment has been
based on assessment of clinical parameters originally
developed for the diagnosis of aGVHD [15]. As such, multiple
MSC infusions have been administered to patients with
persistent diarrhea in the absence of conﬁrmatory histolog-
ical evidence of GI aGVHD. However, persistent diarrhea has
been described after resolution of GI aGVHD documented by
histology [16]. In addition, studies of the effect of MSC infu-
sion in other inﬂammatory bowel diseases, such as Crohn’s
disease, included endoscopic evaluation after MSC infusion
as an endpoint of treatment response [17,18]. This indicates
that the assessment of serial GI biopsy specimens might be
necessary for evaluating the response to experimental
interventions in these patients. Obtaining biopsy specimens
might not be feasible in all cases, however, and thus alter-
native predictors of response should be explored.
Serum biomarkers, including IL-8, TNF receptor 1 (TNFR1),
IL-2 receptor alpha (IL-2Ra), and hepatocyte growth factor
(HGF), have been identiﬁed as supportive markers toTransplantation. Published by Elsevier Inc. All rights reserved.
Table 1
Characteristics of the 22 Children with Severe GI aGVHD
Characteristic Value
Follow-up, days, median (range) 379 (242-2708)
Diagnosis
Acute lymphoblastic leukemia/acute myelogenous
leukemia
9
Other hematologic malignancies 6
Nonmalignant disorder 7
Relapse after HSCT, n 3
Age at HSCT, y, median (range) 6.3 (0.7-18.1)
Sex, male/female, n 12/10
Donor, n
HLA-identical related 7
Matched unrelated donor 5
Mismatched unrelated donor 10
Stem cell source, bone marrow/PBSCs/cord blood, n 13/4/5
Donor sex, male/female, n 12/10
Conditioning, n
Total body irradiationebased myeloablative
conditioning
5
Busulfan-based myeloablative conditioning 14
Other myeloablative conditioning 2
Reduced-intensity conditioning 1
Serotherapy, rATG/Campath, n 13/3
GVHD prophylaxis, n
Cyclosporin A 7
Cyclosporin A þ methotrexate 10
Cyclosporin A þ prednisolone 1 mg/kg 5
aGVHD organ involvement, n
GI only 2
GI and skin 10
GI and liver 5
GI, skin, and liver 5
aGVHD grade III/IV, n 14/8
aGVHD GI stage 2/3/4, n 22/16/4
Time from onset of aGVHD to ﬁrst MSC, d, median
(range)
12 (5-59)
Other second-line therapy, n
Total 6
Steroids 3-5 mg/kg 5
Mycophenolate mofetil/tacrolimus 3
PBSC indicates peripheral blood stem cell; rATG, rabbit antithymocyte
globulin.
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treatment and outcome of aGVHD [19,20]. In addition, serum
concentrations of tissue-speciﬁc biomarkers, including
regenerating islet-derived 3 alpha (REG3a) [21], soluble
cytokeratin 18 (CK18) fragments (sCK18f) [22], and throm-
bomodulin (sTM) [23] for GI aGVHD and elaﬁn [24] for skin
aGVHD, have been correlated with local tissue damage.
However, the usefulness of these markers has not been
investigated systematically or compared with serial biopsy
specimens obtained during MSC treatment of steroid-
refractory aGVHD.
In our center, a substantial pediatric cohort has been
treated with MSCs for steroid-refractory aGVHD involving the
gut in an institutional ethically approved nonrandomized
study. GI biopsy specimens were obtained at the onset of
aGVHD and after MSC infusion. The present study focused on
the relevance, safety, and feasibility of performing GI endos-
copy to obtain biopsy specimens during experimental trials on
aGVHD, and investigated the added value of different bio-
markers in objectively evaluating the effect of MSC infusion.
PATIENTS AND MATERIALS
Patients
Children diagnosed with grade III/IV steroid-refractory aGVHD after
allogeneic hematopoietic stem cell transplantation (HSCT) were treated
with MSCs (protocol LUMC-MEC P05-089). For the purpose of this study,
steroid-refractory aGVHD was deﬁned as progression of symptoms at
72 hours or no improvement or worsening at 7 days after initiation of
methylprednisolone (2 mg/kg/day). All eligible pediatric patients (n ¼ 22),
age 0 to 18 years, who underwent HSCT in the pediatric stem cell transplant
unit of Leiden University Medical Center between January 2005 and
November 2012 were included in this study. Five of these patients were
previously reported in a multicenter analysis of outcomes of MSC therapy
for aGVHD [9]. Patients referred to our center solely for MSC infusions were
not included in this analysis. General patient and transplant characteristics
are summarized in Table 1. The median duration of follow-up of survivors
after HSCT was 379 days (range, 242 to 2708 days).
MSC expansion, characterization, and quality control have described
previously [9]. Patients received third-party bone marrowederived
expandedMSCs in doses ranging from 1.0 to 2.0 10e6MSCs/kg at amedian
of 12 days after initiation of steroids. A median of 2 (range, 1 to 3) MSC
infusions was given. Subsequent MSC infusions were administered to 18
patients for persistent or recurrent symptoms during reduction of phar-
maceutical aGVHD therapies at a median of 14 days (range, 7 to 42 days),
with the majority (14 of 18) receiving a subsequent infusion within 28 days
after the ﬁrst MSC infusion. No patient received additional pharmacologic
immunosuppression after MSC infusion. Six patients with a partial response
who remained steroid-dependent received a third MSC infusion at a median
of 50 days (range, 24 to 97 days) after the ﬁrst MSC infusion.
Endoscopy, Biopsy, and Pathology Report
The diagnosis of GI aGVHD was histologically conﬁrmed in 19 patients
according to published criteria [25], at 5 days after the ﬁrst MSC infusion in
1 child and before the start of MSC therapy in the other 18 children. Endo-
scopic procedures to obtain biopsy specimens were performed by 2 expe-
rienced pediatric gastroenterologists. Five patients underwent 2 endoscopic
procedures before MSC infusion, 2 of whom underwent an additional
endoscopy after negative aGVHD results obtained by proctoscopy. Biopsy
specimens were obtained from the rectum (n¼ 14), lower GI tract (n¼ 5), or
upper and lower GI tracts (n ¼ 5). One patient refused endoscopy and in
2 patients no biopsy specimens were obtained during endoscopy because of
massive inﬂammation and ulceration and an increased risk of perforation.
All 3 of these patients met the clinical criteria for aGVHD. A liver biopsy was
performed in 1 child to conﬁrm liver involvement. Increased bilirubin levels
in combination with conﬁrmed GI and or skin aGVHD was considered to
indicate hepatic aGVHD in 9 patients in whom other underlying liver
pathology (eg, concomitant viral infection, veno-occlusive disease, drug
toxicity) had been excluded.
Patients with persistent or recrudescent diarrhea after MSC infusion
underwent endoscopy to obtain biopsy specimens. Histological examination
of these specimens was performed by 2 pathologists with access to clinically
relevant details, using apoptosis, necrosis, and denudation as characteristics
for aGVHD [25]. An expert panel with extensive experience in pediatric GI
pathology evaluated all biopsy results. In cases of viral infections detectedthrough standard PCR monitoring of serum or plasma for viral reactivation
[26], additional staining was performed to exclude viral enteritis.
Deﬁnitions
Clinical grading of aGVHD was done in accordance with the adapted
Seattle criteria [3]. The response to MSC treatment was documented at
28 days after the ﬁrst MSC infusion, as suggested by MacMillan et al. [27]. A
complete response (CR) was deﬁned clinically as resolution of all symptoms
of aGVHD; partial response (PR), as improvement by at least 1 overall grade;
and no response (NR), as worsening of disease or no improvement.
Two different time points related to the course and initial treatment of
aGVHD before MSC infusion were deﬁned: onset of GI aGVHD and start of
systemic methylprednisolone administration.
Biomarkers
Serum samples were collected and stored at 20C under protocols
approved by the local Ethical Committee (LUMC-MEC P01-028/P03-061).
Serum biomarker concentrations were measured in samples obtained
before conditioning, on the day of HSCT, and weekly starting 2 weeks before
the onset of aGVHD. Additional samples were obtained immediately before
the ﬁrst MSC infusion and weekly thereafter for 4 weeks, followed by
2 weekly samplings for another 4 weeks.
Systemic biomarkers (TNFR1, IL-2Ra, HGF, and IL-8), organ-speciﬁc
markers (CK18, sCK18 F, and REG3a), and sTMweremonitored in all patients
using ELISA in accordance with the manufacturer’s instructions. Manufac-
turer details, serum dilutions, and lower and upper detection limits are
provided in Table S1.
Statistical Analysis
Survival analysis and nonrelapse mortality (NRM) were modeled with
the log-rank Mantel-Cox test. The Mann-Whitney test was used to compare
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treatment. Receiving operating characteristic (ROC) curves with area under
the curve (AUC) values were constructed to deﬁne the discriminatory value
of the biomarkers. Differences in serum biomarker concentrations at various
time points were assessed using the paired Wilcoxon signed-rank test. The
chi-squared test was performed on categorical data. Prism 5 (GraphPad
Software, La Jolla, CA) and SPSS 20 (IBM, Armonk, NY) were used for the
statistical analyses.
RESULTS
Effect of MSC and clinical evaluation of included patients
All 22 patients experienced worsening of symptoms or
stable disease after the start of systemic steroid administra-
tion (2 mg/kg/day). Only 6 patients received additional
immunosuppression with high-dose steroids (5 mg/kg/day),
tacrolimus, or mycophenolate mofetil as second-line therapy
beforeMSC infusion; however, no improvement of skin, liver,
or gut symptoms was seen. The remaining children received
onlyMSC infusion as additional immunosuppressive therapy.
The response documented at day 28 after the ﬁrst MSC
infusion was CR in 11 patients (50%), PR in 6 patients (27%),
and NR in 5 patients (23%). Overall survival was signiﬁcantly
better in patients with CR (P ¼ .027) compared with those
with PR or NR (Figure 1A). Patients with CR had a signiﬁ-
cantly lower NRM (P ¼ .01) than those with PR or NR, as re-
ported previously [9] (Figure 1B). Response rates categorized
according to aGVHD grade, GI stage, and organs affected are
summarized in Table S2. The response rate for GI aGVHDwas
not dependent on the overall aGVHD grade, stage of GI GVHD,
or involvement of other organs. Children with CR were more
likely to undergo HSCT for a malignant disease and with
a graft from an HLA-identical sibling donor, and as such,
signiﬁcantly more children with CR received either no sero-
therapy or serotherapy with cyclosporin A only (Table S3).
Monitoring of viral load using PCR in serum revealed
infection in 14 patients, including 7 cases of cytomegalovirus
infection, 7 cases of adenovirus infection, and 5 cases of
Epstein-Barr virus infection. The presence of viremia did not
inﬂuence the response to MSC treatment. Three patients who
achieved CR relapsed from their underlying malignancy at
days þ332, þ358, and þ511 after HSCT, including 2 of 4 chil-
dren who underwent HSCT for relapsed or refractory acute
myelogenous leukemia or acute myelogenous leukemia/
myelodysplastic syndromeand1of5 childrenwhounderwent
HSCT for high-risk or relapsed acute lymphoblastic leukemia.
GI Biopsy Specimens Collected after MSC Infusion Are
Highly Informative
Persistent diarrhea was observed in 18 children after the
ﬁrst MSC infusion. According to the study protocol, theseFigure 1. Clinical response to MSC salvage therapy. Response to MSC treatment of ch
on day 28 after ﬁrst MSC infusion. Patients with CR have signiﬁcantly better overall s
statistical analysis.patients were eligible for additional MSC infusions. Twelve of
these patients underwent GI endoscopy (3 lower GI and 9
lower and upper GI) with biopsy at a median of 33 days
(range, 19 to 59 days) after the ﬁrst MSC infusion. The clinical
decision making process for these patients is summarized in
a ﬂowchart in Figure 2A. In 4 of these 12 patients, GI
histology showed active aGVHD. These 4 patients received
additional MSC infusions, and 3 subsequently achieved CR.
At the start of the study, persistent diarrhea was an
indication for subsequent MSC infusions, and 4 children
received MSCs accordingly despite reports of negative
histological ﬁndings received later. Four other patients did
not receive additional MSC infusions based on negative
ﬁndings on endoscopy (Figure 2B and C). Accordingly, the
study protocol was amended to provide subsequent MSC
infusion only to patients with histopathological features of
aGVHD.
A protocol violation and 2 refusals led to MSC infusion
without previous endoscopic assessment, and these 3
patients achieved CR. Three other patients were deemed
unﬁt owing to worsening symptoms with multiple comor-
bidities and died from ongoing aGVHD despite additional
MSC infusions.
One patient with documented Klebsiella bacteremia
deteriorated after the endoscopic procedure despite appro-
priate antibiotic therapy. He died frommultiple organ failure
with no evident aGVHD in postmortem samples. No infec-
tious complications associated with the procedure or any
documented side effects, such as hemorrhage, GI perforation,
or intraoperative complications, occurred in any of the other
patients.
Serum Biomarker Concentrations Are Increased at the
Onset of aGVHD
The serum concentrations of the various biomarkers at
the 2 different time points related to the course and initial
treatment of aGVHD were compared with those measured at
7 days before these respective time points. All of the
biomarkers in the panel for aGVHD deﬁned by Paczesny et al.
[19] were increased signiﬁcantly during the progression of
aGVHD to grade II or higher requiring systemic steroid
therapy (Figure S1A-D). In addition, levels of CK18, sCK18F,
and REG3a were signiﬁcantly elevated at the onset of GI
symptoms (Figure S1E-G). In agreement with ﬁndings re-
ported by Luft et al. [23], sTM serum concentrations were not
increased at this time point (Figure S1H). Before HSCT, all but
1 patient had an sTM concentration above the cutoff of 8 ng/
mL, which has been proposed to be predictive for NRM
(Figure S2) [23].ildren with steroid-refractory aGVHD of the GI tract was documented clinically
urvival (A) and lower NRM (B). Log-rank Mantel-Cox tests were performed for
Figure 2. Flow diagram of patients with persistent symptoms. (A) The decision to infuse additional MSC was guided by the results obtained by endoscopy with
biopsies in children with persistent or recurrent diarrhea. (B) Endoscopic evaluation of grade IV aGVHD before MSC infusion showing hemorrhage, denudation of the
epithelium and ulceration. Histological examination was consistent with aGVHD. (C) Repeat endoscopy 22 days after MSC infusion showed evident healing of mucosa
despite persistent diarrhea. Histological examination did not reveal active GVHD.
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Longitudinal analysis of the data obtained for the various
GI biomarkers revealed large interindividual variations. Five
children with extensively documented and histology-
conﬁrmed GI aGVHD had a REG3a concentration <50 ng/
mL. Response toMSC infusionwas not related to the different
patterns shown in Figure S3A-C.
No increases in CK18 and sCK18F concentrations were seen
despite the occurrence of GI aGVHD (Figure S3E and H). A subset
of patients with elevated CK18 and sCK18F exhibited a steep
decline in serum concentrations at the start of MSC infusion
(Figure S3D and G). Interestingly, no patients who achieved CR
demonstrated this phenomenon (Figure S3F and I).
Although higher concentrations of sCK18F have been re-
ported in patients with liver involvement [28], we wereunable to conﬁrm this ﬁnding in our patients with (n¼ 10) or
without (n ¼ 12) liver involvement (data not shown).
TNFR1 Concentration at the Onset of aGVHD Is Predictive
of Response to MSC Infusion
In this analysis, we compared serum concentrations of all
biomarkers between the patients who achieved CR (n ¼ 11)
and those who achieved PR/NR (n ¼ 11). TNFR1 concentra-
tions at the start of systemic corticosteroid therapy were
lower in patients who achieved CR at day 28 after the ﬁrst
MSC infusion (P ¼ .049) (Figure 3A). A TNFR1 cutoff of
4100 pg/mL was predictive for CR and PR/NR, with a sensi-
tivity of 63.6% (95% conﬁdence interval [CI], 30.8% to 89.1%)
and speciﬁcity of 72.7% (39.0% to 93.9%) at the onset of
aGVHD and a sensitivity of 60.0% (95% CI, 26.2% to 87.8%) and
Figure 3. TNFR1 discriminate between patients with a CR and PR/NR on MSC treatment. At the start of systemic corticosteroids and 28 days after infusion of the ﬁrst
MSC serum TNFR1 concentrations (A), but not IL-2Ra (B) or REG3a (C), are signiﬁcantly lower in patients with CR on day 28 compared with patients with PR or NR.
ROC curves are shown at the different time points for TNFR1 (A). (D) Ratio of sCK18F versus CK18 after MSC discriminates between CR and PR/NR. P values for the
different time-points using AUC (A) and Mann-Whitney tests (A-D) are depicted.
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ﬁrst MSC infusion, as deﬁned by ROC curves (Figure 3A).
Concentrations of other biomarkers (eg, IL-2Ra, REG3a) did
not differ between patients with CR and those with PR/NR
(Figure 3B and C).
At the onset of GI aGVHD and the start of MSC therapy, the
ratio of sCK18F to total CK18 was similar in the CR and PR/NR
groups (ratio, 0.4). After initiation of MSC therapy, the
sCK18F:CK18 ratio, including all values with sCK18F >200 U/
L, was signiﬁcantly lower in the PR/NR group (Figure 3D).
Serum Biomarkers Predict Survival
We compared serum concentrations of the various
biomarkers at the different time points between patients
whowere alive (n¼ 14) and thosewhowere not alive (n¼ 8)
at 1 year after HSCT. Relapse-related death did not occur
during the ﬁrst year after HSCT in this cohort. Patients with
a TNFR1 concentration below the median level at the start of
systemic corticosteroids had signiﬁcantly better survival
(P ¼ .012) compared with those with a concentration above
the median level (Figure S4).
At day 28 after the ﬁrstMSC infusion, HGF, TNFR1, IL-8 and
REG3a concentrationswere signiﬁcantly increased inpatients
not alive at 1 year post-HSCT (Figure 4A-D). Applying the
median values as cutoff levels (HGF, 2063 pg/mL; TNFR1,
3980 pg/mL; IL-8, 80 pg/mL; REG3a, 36 pg/mL), TNFR1 and
REG3a concentrations were predictive of survival censored
for relapse (Figure 4A-D). No signiﬁcant differences in IL-2Ra,
CK18, or sCK18F concentrationswere observed between the 2
groups (P¼ .941, .086, and .881, respectively; data not shown).
Biomarker Concentrations are Illustrative at Time of
Biopsy
The diagnostic value of biomarkers was compared with
the histochemical evaluation of GI biopsy specimens. Inde-
pendent of the timing of endoscopy, IL-2Ra, REG3a, CK18,
and sCK18F concentrations were signiﬁcantly higher in sera
obtained from patients in whom GI aGVHD was histopath-
ologically conﬁrmed compared with sera from patients in
whom aGVHD was histopathologically excluded (Figure 5A
and B). Separate analyses of serum biomarkers at the time of
biopsy afterMSC infusion showed a trend toward lower CK18
and sCK18F levels (P ¼ .08 and .15, respectively) in biopsy-
negative GI aGVHD (n ¼ 13 sample dates) compared with
biopsy-positive ongoing aGVHD (n ¼ 8) (Figure 5C).
DISCUSSION
Here we report the largest single-center cohort of chil-
dren treated with MSCs for aGVHD to date in whom
sequential GI biopsy specimens and serum biomarkers were
analyzed to evaluate response to treatment. Five patients
included in this study have been reported in a previous study
on safety of MSC administration [9] that did not focus on the
relevance of biopsy specimens and serum biomarkers.
Response to MSC was scored at day þ28 after the ﬁrst MSC
infusion, which was recently proposed as the optimum
endpoint for evaluating response to treatment [27]. Six
patients without CR received a third MSC infusion after
day þ28, and 5 of these patients subsequently achieved
complete resolution of symptoms. Not unexpectedly, when
the efﬁcacy of MSC infusion was analyzed as the best-ever
response, CR rates were higher compared with the
response at day þ28 (CR, 16 vs 11; PR, 2 vs 6; NR, 4 vs 5).
Ideally, diagnosis of aGVHD as deﬁned by the Seattle
clinical criteria should be conﬁrmed by biopsy of the targetorgan [29]. Previous studies of MSC therapy in children lack
conﬁrmatory biopsy data. The present study indicates that
obtaining GI biopsies is safe and feasible in the majority
(86%) of patients with extensive aGVHD. This is especially
relevant in patients entered in experimental clinical studies
of MSCs, extracorporeal photopheresis [30,31], anti-TNF
[32,33], and mammalian target of rapamycin inhibitors [34].
Irrespective of the treatment under investigation, pub-
lished data continue to deﬁne response based solely on
clinical criteria established primarily for diagnosis. These
criteria can be unreliable in GI aGVHD, especially in children,
given that postinﬂammatory villous atrophy resulting from
extensive damage of the GI epithelium is a recognized
complication after severe aGVHD [16]. In light of this
potential bias, the patients in our cohort underwent both
diagnostic and post-treatment assessment of the GI tract,
including biopsy analysis in patients with persistent clinical
symptoms, to reliably document their response to MSC
salvage treatment. A high incidence (18 of 21 cases) of
persistently profuse diarrhea after ﬁrst MSC infusion was
documented. On biopsy analysis, the majority of children (8
of 12) demonstrated no histological evidence of active
aGVHD. Non-GVHD villous atrophy and introduction of oral
feeding might have caused malabsorption and subsequent
osmotic diarrhea. The distinction between persistent aGVHD
and diarrhea from other causes allowed for the pertinent use
of MSC infusion and subsequently altered the clinical
management of these patients. The reliability of this
approach is supported by our ability to successfully reduce
immunosuppression in patients without aGVHD after MSC
infusion, whereas in the majority of patients with ongoing
aGVHD, additional MSC infusions resulted in complete
resolution of the disease. Moreover, feeding regimens could
be tailored in children with postinﬂammatory villous
atrophy.
Owing to Ethical Committee and safety concerns, GI
biopsy specimens were obtained only for clinical indications,
and unlike serum biomarkers, they were not available at
ﬁxed time points. Because the timing of biopsy varied, an
analysis based on histological deﬁnitions on day þ28 after
MSC infusion was not possible.
Despite its demonstrated usefulness and safety proﬁles,
endoscopy with biopsy is an invasive procedure requiring
general anesthesia in children. In a large multicenter study,
especially in centers lacking pediatric gastroenterology
expertise, obtaining biopsy specimens might not be feasible.
Thus, we determined the value of biomarkers in relation to
response as determined by clinical and pathological ﬁndings.
The biomarkers studied in our patient cohort conﬁrm the
previously reported increases in inﬂammatory and GI-
speciﬁc biomarkers at the onset of aGVHD.
Measurement of CK18 and sCK18F measured in serum at
the time of biopsy has the potential to serve as an alternative
diagnostic tool. Levels of both total protein and cleaved
fragments were signiﬁcantly increased at the time of positive
GI biopsy compared with negative biopsy. The sensitivity
(53.8% in the present study; 95% CI, 25.1% to 80.8%) and
speciﬁcity (86.7% in the present study; 95% CI, 69.3% to
96.2%) of the CK18 test remain to be validated in larger
patient cohorts, however. In addition, biomarkers not
achieving statistic signiﬁcance in our cohort should be
evaluated as potential alternatives to serial biopsies in future
studies. Our observed decrease in the sCK18F:CK18 ratio in
patients not responding to MSC infusion suggests the
occurrence of apoptosis-independent cell death after MSC
Figure 4. Serum biomarkers at 28 days after the ﬁrst MSC are predictive for survival. HGF (A), TNFR1 (B), IL-8 (C), and REG3a (D) concentrations in available samples
at day þ 28 after the ﬁrst MSC infusion are increased in patients not alive at 1 year after transplantation. Using the median as a cutoff value, patients with low TNFR1
and low REG3a concentrations have a signiﬁcantly better survival. The dotted horizontal line in the left panels represents the median of all values. Closed, half open
and open symbols were used for CR, PR, and NR at day 28 after MSC infusion, respectively. Statistics were performed using Mann-Whitney (left panels) and log-rank
(right panels) tests.
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Figure 5. Concentrations of serum biomarkers at time of GI biopsies. (A) Biomarker concentrations in serum are higher at the time of histological conﬁrmed aGVHD
compared with concentrations in sera taken at the time of negatively scored biopsies. A total of 45 time points at which combined biopsy and serum samples were
available was evaluated independently whether this was before or after the ﬁrst MSC infusion. (B) Sensitivity and speciﬁcity are shown by ROC curves if speciﬁcity
was at least 80%. (C) Focusing on paired biopsy and serum samples obtained after MSC infusion, biomarker concentrations do not differ signiﬁcantly between samples
collected at the time of a positive or negative biopsy. Depicted P values were derived from Mann-Whitney (A and C) or AUC (B).
F.G.J. Calkoen et al. / Biol Blood Marrow Transplant 19 (2013) 1590e1599 1597infusion in these patients. This is in line with observations
reported by Jitschin et al. [35] in patients with steroid-
refractory aGVHD or hemorrhage treated with MSCs.In accordancewith von Bahr et al. [36], we found lower IL-
2Ra concentrations at 7 days after MSC infusion, which was
not correlated with the response toMSCs. This is reminiscent
F.G.J. Calkoen et al. / Biol Blood Marrow Transplant 19 (2013) 1590e15991598of the previously described decline in IL-2Ra concentrations
in both patients responding to steroids and those refractory
to steroids [22]. In contrast, Dander et al. [37] reported
a correlation of biomarkers IL-2Ra and TNFR1 with the
response to MSC treatment in 10 patients with aGVHD or
chronic GVHD; however, the timing of the measurement
with regard to the sequential number of MSC infusions in
that study is unclear.
Selected biomarkers have demonstrated predictive value
in terms of the response to treatment and survival at
multiple time points before and after MSC infusion. Although
these data are based on a limited number of patients, they
support the stratiﬁcation in clinical trials based on
biomarkers, as suggested by Paczesny [20], at the time of
diagnosis or the start of salvage therapy. However, the wide
variation in biomarker patterns observed in our patient
cohort after MSC treatment does not allow for the substitu-
tion of a biomarker panel for biopsy analysis to evaluate
response and guide clinical decision making in individual
patients. Our data remain to be validated in largemulticenter
studies, which are currently under development.
REG3a levels were lower in our patient cohort compared
with the American cohort reported by Ferrrara et al. [21], but
in linewith levels reported in the Regensburg (Germany) and
Kyushy (Japan) cohorts described in the same paper. Unlike
the patients in the American cohort, all of the patients in our
cohort received selective GI decontamination with poly-
myxin, neomycin, and amphotericin B or total GI decon-
tamination with piperacillin, tazobactam, and amphotericin
B [38]. REG3a is secreted in response to bacteria, and the
lower REG3a concentrations in our cohort might be related
to the suppression of bacterial microﬂora [39]. Even at the
lower levels of REG3a, the concentrations were correlated
with aGVHD and were predictive of survival.
Alongwith serum biomarkers, stool and urine biomarkers
also have been proposed [40,41]. These materials were not
available for analysis in the present retrospective study.
Collection of uncontaminated urine from children with
aGVHD at multiple time points is difﬁcult, and analysis of
stool samples for the measurement of procalcitonin in a pilot
study at our center was complicated by the collection of
insufﬁcient material in young children (data not shown).
The present study demonstrates the importance of crit-
ical and intensive monitoring of patients included in an
experimental study. Before the introduction of MSC therapy,
experience with children surviving severe aGVHD was
limited. A new phenomenon, persistence of severe villous
atrophy after resolution of aGVHD causing severe protracted
diarrhea, was identiﬁed. Endoscopy with biopsy remains
the gold standard for differentiating between active aGVHD
and postinﬂammatory villous atrophy. In the later phase of
this trial, additional MSC infusions were provided based
only on clinical symptoms in combination with histological
results.
Further recommendations for studies of steroid-
refractory aGVHD that allow for comparative observation
among variousmodalities of treatment are needed. Response
criteria and timing of assessment of response remain to be
deﬁned, preferably through consensus of transplantation
organizations, such as the Center for International Blood and
Marrow Transplantation Research and the European Group
for Blood andMarrow Transplantation. Based on our ﬁndings
reported here, these criteria should include biopsy analysis
and serial serum biomarker concentrations at diagnosis and
after treatment in patientswith persistent clinical symptoms.ACKNOWLEDGMENTS
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